Search Results 841-850 of 17522 for Assay

1. A Phase Ⅲ Study Of Rilvegostomig In Combination With Fluoropyrimidine And Trastuzumab Deruxtecan As The First-line Treatment For HER2-positive Gastric Cancer - Mayo Clinic

   Note: If the participants' PD-L1 expression has already been assessed using same assay, testing platform, and scoring manual as part of the screening ...

2. A Study of Taxane, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Metastatic Breast Cancer Patients - Mayo Clinic

   ... assay; positive is defined as IHC 3+ staining intensity; if HER2 IHC results ... assay, use ≤ 1.5 as the value for the ULN; patients receiving anti ...

3. Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma - Mayo Clinic

   ... assay) within 14 days of RPLND -Eastern Cooperative Oncology Group (ECOG) performance status =< 1 -Ability to understand and the willingness to sign a ...

4. Thyroid Cancer Clinical Trials - Mayo Clinic Research

   5) are safe for people with specific delta-like protein 3-expressing cancers. cfDNA Assay ... assays to detect cancer early in blood. The purpose of this ...

5. Rectal Cancer Clinical Trials - Mayo Clinic Research

   To evaluate the ability of the plasma MDM assay to predict CRC recurrence when tested serially following curative resection of CRC metastases. A Study of ...

6. A Registry to Form a Long-Term Therapeutic and Research Network for Hepatitis C - Mayo Clinic

   Studies comparing HCV RNA assays are not considered exclusionary. Participating Mayo Clinic locations. Study statuses change often. Please contact the study ...

7. Prerequisites and Requirements - M.D. Program - Mayo Clinic Alix School of Medicine

   The preferred method of testing is by Interferon-Gamma Release Assay (IGRA). This lab must be drawn within three months prior to program start ...

8. Hepatocellular Carcinoma (HCC) Clinical Trials - Mayo Clinic Research

   ... assays for detection of hepatocellular carcinoma (HCC). Study to Evaluate Chemoembolization Combined with Durvalumab and Bevacizumab Therapy in Patients ...

9. A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) - Mayo Clinic

   If subject BRAF mutation status is unknown, before randomization the subject must have BRAF testing performed using an approved assay method;; Patients with ...

10. Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial - Mayo Clinic

    ... assays are performed. Chosen ECOG treatment clinical trial must be active and accruing. Patient must not have begun treatment on the ECOG treatment clinical ...